NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Is Up 12.3% After 168% Surge In Q1 2026 Preliminary Revenue - What's Changed
ImmunityBio, Inc. recently reported preliminary first-quarter 2026 net product revenue of approximately US$44.2 million, indicating an approximately 168% year-over-year increase compared with the same period in 2025.
This sharp revenue acceleration puts fresh focus on how quickly ANKTIVA and the broader portfolio are converting clinical progress into commercial uptake.
Next, we’ll examine how this sharp jump in preliminary net product revenue may influence ImmunityBio’s previously outlined...